Atherosclerosis imaging in drug development

Stephen J. Nicholls, Srinivasa Kalidindi, Keon Woong Moon, Steven E. Nissen

Research output: Contribution to journalReview article

Abstract

Increasing use of established medical therapies presents a major challenge for the assessment of experimental antiatherosclerotic agents. The requirement to perform clinical trials with increasing numbers of subjects, followed for longer periods of time, creates a scenario that is largely prohibitive for the development of most new agents. Technologic advances in arterial wall imaging provide the opportunity to evaluate the impact of therapies on the natural history of atherosclerosis. The design and implementation of clinical trials that employ serial imaging of the arterial wall has become increasingly used in the development of new therapies to target atherosclerotic cardiovascular disease.

LanguageEnglish
Pages1241-1250
Number of pages10
JournalExpert Opinion on Drug Discovery
Volume2
Issue number9
DOIs
Publication statusPublished - Sep 2007

Keywords

  • Atherosclerosis
  • Drug development
  • Imaging
  • Risk factor

ASJC Scopus subject areas

  • Drug Discovery

Cite this

Nicholls, S. J., Kalidindi, S., Moon, K. W., & Nissen, S. E. (2007). Atherosclerosis imaging in drug development. Expert Opinion on Drug Discovery, 2(9), 1241-1250. https://doi.org/10.1517/17460441.2.9.1241
Nicholls, Stephen J. ; Kalidindi, Srinivasa ; Moon, Keon Woong ; Nissen, Steven E. / Atherosclerosis imaging in drug development. In: Expert Opinion on Drug Discovery. 2007 ; Vol. 2, No. 9. pp. 1241-1250.
@article{13a489f100f44b929fac347a43b798af,
title = "Atherosclerosis imaging in drug development",
abstract = "Increasing use of established medical therapies presents a major challenge for the assessment of experimental antiatherosclerotic agents. The requirement to perform clinical trials with increasing numbers of subjects, followed for longer periods of time, creates a scenario that is largely prohibitive for the development of most new agents. Technologic advances in arterial wall imaging provide the opportunity to evaluate the impact of therapies on the natural history of atherosclerosis. The design and implementation of clinical trials that employ serial imaging of the arterial wall has become increasingly used in the development of new therapies to target atherosclerotic cardiovascular disease.",
keywords = "Atherosclerosis, Drug development, Imaging, Risk factor",
author = "Nicholls, {Stephen J.} and Srinivasa Kalidindi and Moon, {Keon Woong} and Nissen, {Steven E.}",
year = "2007",
month = "9",
doi = "10.1517/17460441.2.9.1241",
language = "English",
volume = "2",
pages = "1241--1250",
journal = "Expert Opinion on Drug Discovery",
issn = "1746-0441",
publisher = "Informa Healthcare",
number = "9",

}

Nicholls, SJ, Kalidindi, S, Moon, KW & Nissen, SE 2007, 'Atherosclerosis imaging in drug development', Expert Opinion on Drug Discovery, vol. 2, no. 9, pp. 1241-1250. https://doi.org/10.1517/17460441.2.9.1241

Atherosclerosis imaging in drug development. / Nicholls, Stephen J.; Kalidindi, Srinivasa; Moon, Keon Woong; Nissen, Steven E.

In: Expert Opinion on Drug Discovery, Vol. 2, No. 9, 09.2007, p. 1241-1250.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Atherosclerosis imaging in drug development

AU - Nicholls, Stephen J.

AU - Kalidindi, Srinivasa

AU - Moon, Keon Woong

AU - Nissen, Steven E.

PY - 2007/9

Y1 - 2007/9

N2 - Increasing use of established medical therapies presents a major challenge for the assessment of experimental antiatherosclerotic agents. The requirement to perform clinical trials with increasing numbers of subjects, followed for longer periods of time, creates a scenario that is largely prohibitive for the development of most new agents. Technologic advances in arterial wall imaging provide the opportunity to evaluate the impact of therapies on the natural history of atherosclerosis. The design and implementation of clinical trials that employ serial imaging of the arterial wall has become increasingly used in the development of new therapies to target atherosclerotic cardiovascular disease.

AB - Increasing use of established medical therapies presents a major challenge for the assessment of experimental antiatherosclerotic agents. The requirement to perform clinical trials with increasing numbers of subjects, followed for longer periods of time, creates a scenario that is largely prohibitive for the development of most new agents. Technologic advances in arterial wall imaging provide the opportunity to evaluate the impact of therapies on the natural history of atherosclerosis. The design and implementation of clinical trials that employ serial imaging of the arterial wall has become increasingly used in the development of new therapies to target atherosclerotic cardiovascular disease.

KW - Atherosclerosis

KW - Drug development

KW - Imaging

KW - Risk factor

UR - http://www.scopus.com/inward/record.url?scp=34848850742&partnerID=8YFLogxK

U2 - 10.1517/17460441.2.9.1241

DO - 10.1517/17460441.2.9.1241

M3 - Review article

VL - 2

SP - 1241

EP - 1250

JO - Expert Opinion on Drug Discovery

T2 - Expert Opinion on Drug Discovery

JF - Expert Opinion on Drug Discovery

SN - 1746-0441

IS - 9

ER -